Levi & Korsinsky, LLP announces that an AMPE class action lawsuit has been filed on behalf of investors who purchased  Ampio Pharmaceuticals, Inc. (AMPE) This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired Ampio common stock between December 29, 2020, and August 3, 2022, inclusive.  For more on the AMPE Lawsuit please contact us today.

According to the Ampio lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(i) defendants had inflated the Company’s true ability to successfully file a Biologics License Application (“BLA”) for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendant’s statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

TO LEARN MORE ABOUT THE AMPE CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Ampio you have until October 17, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com